Abstract:ABSTRACT BACKGROUND Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene. Immune activation is abundant in the striatum of HD patients. Detection of active microglia at presymptomatic stages suggests that microgliosis is a key early driver of neuronal dysfunction and degeneration. Recent studies showed that deletion of Tyrobp , a microglial-enriched protein, ameliorates neuronal function in Alzheimer’s disease amyloid and tauopathy mouse models while decreasing components of the complement subnetwork, thus raising the possibility that Tyrobp deletion can be beneficial for HD. METHODS To test the hypothesis that Tyrobp deficiency would be beneficial in a HD model, we placed the Q175 HD mouse model on a Tyrobp -null background. We characterized these mice with a combination of behavioral testing, immunohistochemistry, transcriptomic and proteomic profiling. Further, we evaluated the Q175 microglia-specific gene signature, with and without Tyrobp , by purifying microglia from these mice for transcriptomics. RESULTS Comprehensive analysis of publicly available transcriptomic HD human data revealed that TYROBP network is overactivated in HD putamen. The Q175 mice showed morphologic microglial activation, reduced levels of post-synaptic density-95 protein and motor deficits at 6 and 9 months of age, all of which were ameliorated on the Tyrobp -null background. Gene expression analysis revealed that lack of Tyrobp in the Q175 model does not prevent the decrease in the expression of striatal neuronal genes but reduces pro-inflammatory pathways that are specifically active in HD human brain. Integration of transcriptomic and proteomic data identified that astrogliosis and complement system pathway were reduced after Tyrobp deletion. Results were further validated by immunofluorescence analysis. Microglia-specific HD gene dysregulation, characterized by overexpression of neuronal genes, was also not corrected by Tyrobp deletion. CONCLUSIONS Our data provide molecular and functional support demonstrating that Tyrobp deletion prevents many of the abnormalities in the Q175 HD mouse model, in the absence of correction of striatal neuronal gene expression, suggesting that the Tyrobp pathway is a potential therapeutic candidate for Huntington’s disease.

PYK2 in the dorsal striatum of Huntington’s disease R6/2 mouse model

Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease

The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease

Deletion of the microglial transmembrane immune signaling adaptor TYROBP ameliorates Huntington’s disease mouse phenotype

Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum

Rhes Depletion Promotes Striatal Accumulation and Aggregation of Mutant Huntingtin in a Presymptomatic HD Mouse Model.

Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington’s Disease Mice Prior to Onset of Symptoms

Striatal-enriched Protein Tyrosine Phosphatase Expression and Activity in Huntington's Disease: a STEP in the Resistance to Excitotoxicity.

Thalamocortical Projections Are Significantly Impaired in the R6/2 Mouse Model of Huntington's Disease

Corticostriatal Maldevelopment in the R6/2 Mouse Model of Juvenile Huntington Disease

TYROBP/DAP12 knockout in Huntington's disease Q175 mice cell-autonomously decreases microglial expression of disease-associated genes and non-cell-autonomously mitigates astrogliosis and motor deterioration

Corticostriatal Maldevelopment in the R6/2 Mouse Model of Juvenile Huntington's Disease

Developmental alterations of indirect-pathway medium spiny neurons in mouse models of Huntington's disease.

Compromised retinoic acid receptor beta (RARβ) accelerates the onset of motor, cellular and molecular abnormalities in mouse model of Huntington’s disease

Motor skill learning modulates striatal extracellular vesicles' content in a mouse model of Huntington's disease

Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease

Differential contribution of direct and indirect pathways from dorsolateral and dorsomedial striatum to motor symptoms in Huntington's disease mice

Effects of Exogenous Nub1 Expression in the Striatum of Hdq175/Q7 Mice

Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.

Protein Expression in the Striatum and Cortex Regions of the Brain for A Mouse Model of Huntington'S Disease